Subject(s)
Mucocutaneous Lymph Node Syndrome , Adolescent , Age Factors , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Aspirin/administration & dosage , Aspirin/therapeutic use , Female , Follow-Up Studies , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/therapeutic use , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/drug therapy , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/therapeutic use , Time FactorsSubject(s)
Meningitis, Aseptic/etiology , Meningoencephalitis/etiology , Polychondritis, Relapsing/complications , Aged , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Biopsy , Confusion/etiology , Drug Therapy, Combination , Electroencephalography , Female , Hallucinations/etiology , Humans , Magnetic Resonance Imaging , Meningitis, Aseptic/diagnosis , Meningitis, Aseptic/drug therapy , Meningoencephalitis/diagnosis , Meningoencephalitis/drug therapy , Polychondritis, Relapsing/diagnosis , Polychondritis, Relapsing/drug therapy , Prednisone/therapeutic use , Spinal PunctureSubject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents/adverse effects , Cervical Vertebrae/drug effects , Glucocorticoids/adverse effects , Occipital Bone/drug effects , Osteitis/chemically induced , Pregnatrienes/adverse effects , Administration, Oral , Aged , Aged, 80 and over , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cervical Vertebrae/pathology , Drug Therapy, Combination , Female , Glucocorticoids/administration & dosage , Humans , Injections, Intradermal , Injections, Subcutaneous , Magnetic Resonance Imaging , Middle Aged , Occipital Bone/pathology , Osteitis/diagnosis , Pregnatrienes/administration & dosageABSTRACT
BACKGROUND: Although renal function is generally unaffected by liposome formulations of amphotericin B-deoxycholate, there is nevertheless a risk. CASE REPORTS: Two patients immunodepressed patients treated for candidosis involving the mouth and esophagus unresponsive to local care and flucanazol developed renal failure when given the liposome formulation of amphotericin B-deoxycholate (AmBisome). In one with normal renal function prior to treatment, moderate impairment was observed after initiating AmBisome. In the second patient, impaired renal function worsened after initiating treatment with amphotericin B-deoxycholate then progressed to very severe renal failure after switching to AmBisome. CONCLUSION: The indication for AmBisome (amphotericin B-deoxycholate treatment in patients with active renal impairment) must not overshadow the risk of worsening renal function under treatment.
Subject(s)
Amphotericin B/adverse effects , Antifungal Agents/adverse effects , Renal Insufficiency/chemically induced , Adult , Candidiasis/drug therapy , Female , Humans , Immunocompromised Host , Male , Risk FactorsABSTRACT
BACKGROUND: A rising percentage of tetracycline-resistant Propionibacterium acnes strains has been reported in the English literature. PATIENTS AND METHODS: We studied a population of 16 patients with acne who had been treated with oral tetracyclines during the preceding year. A bacteriological examination of a skin biopsy was obtained in all patients to determine aerobic and anaerobic flora as wells as resistance to tetracycline and minocycline. RESULTS: Staphylococcus epidermidis strains were frequently resistant to tetracycline (87.5%) as well as minocycline (30%). Tetracycline-resistant Propionibacterium acnes were also observed (7%). Inversely, we were unable to evidence any minocycline-resistant Propionibacterium acnes strains. CONCLUSION: These findings emphasize the importance of determining whether therapeutic response is related or not to the presence of resistant strains.